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A B S T R A C T
Objective: This retrospective study examined whether changes in patient pre- and post-treatment symptoms
correlated with changes in anti-neuronal autoantibody titers and the neuronal cell stimulation assay in the
Cunningham Panel in patients with Pediatric Autoimmune Neuropsychiatric Disorder Associated with
Streptococcal Infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS).
Methods: In an analysis of all tests consecutively performed in Moleculera Labs' clinical laboratory from April 22,
2013 to December 31, 2016, we identified 206 patients who were prescribed at least one panel prior to and
following treatment, and who met the PANDAS/PANS diagnostic criteria. Patient follow-up was performed to
collect symptoms and treatment or medical intervention. Of the 206 patients, 58 met the inclusion criteria of
providing informed consent/assent and documented pre- and post-treatment symptoms. Clinician and parent-
reported symptoms after treatment or medical intervention were categorized as “Improved/Resolved” (n = 34)
or “Not-Improved/Worsened” (n = 24). These were analyzed for any association between changes in clinical
status and changes in Cunningham panel test results. Clinical assay performance was also evaluated for re-
producibility and reliability.
Results: Comparison of pre- and post-treatment status revealed that the Cunningham Panel results correlated
with changes in patient's neuropsychiatric symptoms. Based upon the change in the number of positive tests, the
overall accuracy was 86%, the sensitivity and specificity were 88% and 83% respectively, and the Area Under
the Curve (AUC) was 93.4%. When evaluated by changes in autoantibody levels, we observed an overall ac-
curacy of 90%, a sensitivity of 88%, a specificity of 92% and an AUC of 95.7%. Assay reproducibility for the
calcium/calmodulin-dependent protein kinase II (CaMKII) revealed a correlation coefficient of 0.90
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(p < 1.67 × 10−6) and the ELISA assays demonstrated test-retest reproducibility comparable with other ELISA
assays.
Conclusion: This study revealed a strong positive association between changes in neuropsychiatric symptoms
and changes in the level of anti-neuronal antibodies and antibody-mediated CaMKII human neuronal cell acti-
vation. These results suggest there may be clinical utility in monitoring autoantibody levels and stimulatory
activity against these five neuronal antigen targets as an aid in the diagnosis and treatment of infection-triggered
autoimmune neuropsychiatric disorders. Future prospective studies should examine the feasibility of predicting
antimicrobial and immunotherapy responses with the Cunningham Panel.
1. Introduction
The biology behind many neuropsychiatric conditions remains
elusive, but recent studies implicate immune dysregulation in some
cases, particularly the presence of autoantibodies targeting neural
tissue. Numerous studies have linked movement, behavior, and neu-
ropsychiatric disorders to infections and the production of anti-neu-
ronal autoantibodies (Kirvan et al., 2003; Cox et al., 2013; Kirvan et al.,
2006a, 2006b; Kirvan et al., 2007; Singer et al., 2015; Brimberg et al.,
2012; Cunningham, 2012, 2014; Garvey et al., 1998; Garvey et al.,
1999; Gause et al., 2009; Greenberg, 2017; Murphy et al., 2007;
Perlmutter et al., 1998; Taranta and Stollerman, 1956; Taranta, 1959;
Swedo, 1994; Cox et al., 2015; Rhee and Cameron, 2012). Infectious
triggers such as streptococcal and other infections, along with anti-
neuronal autoantibodies similar to those associated with Sydenham
chorea have been linked to childhood obsessive-compulsive disorder
(OCD) and/or tics (Kirvan et al., 2003; Kirvan et al., 2006a, 2006b;
Swedo, 1994; Swedo et al., 1998; Swedo et al., 1997; Swedo et al.,
1993; Swedo et al., 1989). When symptom onset is abrupt, Pediatric
Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
Infection (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syn-
drome (PANS) are two disorders used to describe these symptoms. The
diagnostic criteria for PANS is defined as an abrupt onset of OCD or
severely restricted food intake, and the presence of at least two of the
following seven categories: (1) anxiety; (2) emotional lability and/or
depression; (3) irritability, aggression, and/or severely oppositional
behaviors; (4) behavioral (developmental) regression; (5) deterioration
in school performance (related to attention deficit hyperactivity dis-
order-like symptoms, memory deficits, cognitive changes); (6) sensory
or motor abnormalities; (7) somatic signs and symptoms, including
sleep disturbances, enuresis, or increased urinary frequency (Swedo
et al., 1997; Chang et al., 2015).
Since Sydenham chorea has a well-established biological me-
chanism connecting streptococcal infections with autoimmune-induced
neuropsychiatric symptoms, it has been used as a biological model to
better understand PANDAS and PANS (Cunningham, 2012, 2014).
Central nervous system (CNS) autoimmune targets that were originally
identified through multiple studies in patients with Sydenham chorea
were applied to patients with PANDAS. Targets identified to overlap
between Sydenham chorea and PANDAS were used to develop the
Cunningham Panel, a set of blood tests utilized for measuring immune
dysfunction, related to neuropsychiatric conditions associated with an
infectious trigger.
1.1. Biological basis of assays in the Cunningham Panel
The Cunningham Panel includes five assays performed on a serum
sample from blood collected in glass tubes free of any excipients. Four
assays measure human serum Immunoglobulin G (IgG) levels by
Enzyme-Linked ImmunoSorbent Assays (ELISA) directed against 1)
Dopamine D1 Receptor (D1R), 2) Dopamine D2L Receptor (D2LR), 3)
Lysoganglioside-GM1 and 4) Tubulin. A fifth assay is a cell stimulation
assay which measures the ability of a patient's serum immunoglobulin
G (IgG) to stimulate calcium/calmodulin-dependent protein kinase II
(CaMKII) activity in human neuronal cells. We briefly review the
biological basis for the selection of these five assays below. (See Fig. 1)
1.1.1. Anti-Lysoganglioside GM1 assay
Commercially available measurements of human group A strepto-
coccal (GAS) antibodies (i.e., ASO and/or anti-DNase B antibodies) are
sufficient for measuring GAS reactivity, but do not provide any re-
lationship to GAS-related autoimmune reactivity and the CNS. Using
human monoclonal antibodies derived from Sydenham chorea patients,
Cunningham and Kirvan observed significant cross-reactivity against
neurons in the human basal ganglia (Kirvan et al., 2003) and against N-
acetyl-beta D-glucosamine (GlcNAc), the major constituent of the GAS
cell wall, a carbohydrate epitope. They observed strong cross-reactivity
against the neuronal surface antigen lysoganglioside GM1 but not
against other gangliosides (Kirvan et al., 2003; Kirvan et al., 2007).
Lysoganglioside GM1 antigen also blocked binding of these auto-
antibodies to human caudate and putamen, demonstrating specific
neural targets in the brain center known to be involved in movement
disorders such as chorea, tics and motor stereotypies, whereas these
serum autoantibodies receded to normal levels during convalescence. In
addition, IgG derived from the serum or cerebrospinal fluid (CSF) of
Sydenham chorea and PANDAS patients was found to target human
caudate and putamen brain tissue, and this reaction could be inhibited
by lysoganglioside GM1 (Kirvan 2006; Kirvan et al., 2006a, 2006b).
Fig. 1. Autoantibodies directed against Dopamine D1/D2 Receptors and
Lysoganglioside GM1, and CaMKII activation. Reprinted by permission from
Springer Nature: Nature Reviews Disease Primers, Carapetis et al. Volume 2,”
Acute Rheumatic Fever and Rheumatic Heart Disease.” 2016.
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1.1.2. CaMKII cell stimulation assay
Integrated into the Cunningham Panel is the measurement of
CaMKII activation which is mechanistically important since activation
increases the activity of tyrosine hydrolase, an enzyme that produces
dopamine, resulting in increased dopamine output, a key neuro-
transmitter involved in movement disorders. Both IgG from sera and
CSF of PANDAS patients were found to signal activation of CaMKII in
human neuronal cells (Kirvan et al., 2006a, 2006b). Supporting the
specificity of GAS antibodies causing CaMKII activation, it was de-
monstrated that activation was blocked by streptococcal-associated
GlcNAc or by depleting immunoglobulins from serum and CSF by af-
finity column adsorption (Kirvan et al., 2006a, 2006b). Additional data
showed that CaMKII was activated 202% above basal level in Sy-
denham chorea and PANDAS patients during the acute phase, whereas
convalescent serum collected in the absence of chorea showed no sig-
nificant increase in CaMKII activity (Kirvan 2003). Finally, additional
studies have shown that patient symptom improvement was associated
with a reduction in CaMKII activation.
CaMKII is also involved in the regulation of N-methyl-D-aspartate
(NMDA) receptor excitability via glutamate transmission (Hell, 2014)
which is being recognized in syndromes which include OCD, tics, and
Tourette Syndrome (Marsili et al., 2017), and being recognized as a
treatment target in OCD (Laoutidis et al., 2016). Mutations in CAMK2A
and CAMK2B, the genes that code for CaMKII, have been associated
with intellectual disability (Kury et al., 2017) and ASD-related beha-
viors such as hyperactivity, social interaction deficits, and repetitive
behaviors (Stephenson et al., 2017). Other studies have linked CaMKII
to the pathogenesis and symptoms in a variety of mental and neuro-
logical illnesses, including learning disorders, cognitive impairment,
schizophrenia (Robison, 2014; Kury et al., 2017), ischemia, Alzheimer's
disease (Ly and Song, 2011; Ghosh and Giese, 2015), epilepsy (Zhang
et al., 2014; Robison, 2014) and Parkinson's disease (Zhang et al., 2014;
Zaichick et al., 2017).
1.1.3. Anti-dopamine D1 and D2L receptor
The inclusion of dopamine D1 and D2L receptors as targets arose
from studies that demonstrated autoantibodies directed against dopa-
mine D1 and D2L receptors correlated with various neuropsychiatric
symptoms (Ben-Pazi et al., 2013). Two types of anti-neuronal human
antibodies against the dopamine receptors induced an increase in do-
pamine neurotransmitter release (Kirvan et al., 2006a, 2006b). D1 and
D2L receptor antibodies were elevated in patients with Sydenham
chorea and PANDAS compared to controls (Kirvan et al., 2003; Kirvan
et al., 2006a, 2006b; Kirvan et al., 2007; Cox et al., 2013; Cox et al.,
2015; Cunningham and Cox, 2016), and are likely important in pa-
thogenesis of neuropsychiatric diseases associated with infection
(Singer et al., 2015; Brimberg et al., 2012).
1.1.4. Anti-tubulin
Human monoclonal antibodies derived from patients with
Sydenham chorea, reacted with human caudate and putamen brain
sections and reactivity was blocked by anti-tubulin monoclonal anti-
bodies. The reactive epitope of these brain proteins was found to be a N-
terminal amino acid sequence with corresponding homology to β-tu-
bulin (Kirvan et al., 2007). Tubulin autoantibodies have also been
identified in chronic inflammatory demyelinating polyneuropathy and
Guillain-Barré syndrome (Connolly and Pestronk, 1997), Graves' dis-
ease and Hashimoto's thyroiditis (Rousset et al., 1983).
1.2. Purpose of this study
The purpose of our study was to determine if, and to what extent,
the assays of the Cunningham Panel parallel changes in PANDAS/PANS
symptoms with treatment. Since immunomodulatory treatment for
neuropsychiatric conditions can have positive (Perlmutter et al., 1999;
Kovacevic et al., 2015) but also variable (Williams et al., 2016) out-
comes, the ability to predict responsiveness to immunomodulatory
treatments would be of high value. As a step towards this goal, this
study examines whether the assays within the Cunningham Panel are
potential biological markers that can be used to follow changes in
symptoms with treatment, and could potentially be used to predict
response to immunomodulatory treatment.
2. Methods
2.1. Subjects
All patients presented with various neuropsychiatric symptoms
characteristic of the criteria for PANS/PANDAS and were either diag-
nosed with, or suspected of, PANS/PANDAS at the time of their first test
requisition (Table 1). Fifty eight of 206 subjects who were identified to
have had a Cunningham Panel from April 22, 2013 through Dec. 31,
2016, had two or more panels performed and met the inclusion criteria
(see Fig. 2). Documentation of patient symptoms was received by direct
Table 1
Summary of symptoms of PANS/PANDAS patients included in this study by individual patients in Group 1: improved/resolved and Group 2: not improved/worsened.
Symptom Group 1
Improved/resolved
Group 2
Not Improved/worsened
Combined
All patients
Count
(N = 34)
Percent Count
(N = 24)
Percent Count
(N = 58)
Percent
Decreased concentration 31 91% 22 92% 53 91%
OCD 34 100% 18 75% 52 90%
Emotional lability or depression 30 88% 19 79% 49 85%
Sensory symptoms 26 77% 22 92% 48 83%
Anxiety: general and/or Separation 26 77% 22 92% 48 83%
Sleep disorders 29 85% 15 63% 44 76%
Aggressiveness 27 79% 17 71% 44 76%
Tics 22 65% 21 88% 43 74%
Motor symptoms 19 56% 23 96% 42 72%
Developmental regression 23 68% 19 79% 42 72%
Dysgraphia 22 65% 18 24% 40 69%
Urinary urgency or frequency 15 44% 11 46% 26 45%
Chorea/choreiform movements 12 35% 13 54% 25 43%
Behavioral regression 8 24% 1 4% 9 16%
Anorexia or ARFID 3 9% 3 13% 6 10%
Psychosis 4 12% 1 4% 5 9%
OCD = obsessive compulsive symptoms; ARFID = avoidant/restrictive food intake disorder.
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phone and/or email communication with the prescribing clinician or
parents, supported by documented call notes in our Laboratory In-
formation Management System (LIMS). Clinician or parent assessments
were specific to improvement or non-improvement compared to their
initial presentation of symptoms when the first panel was performed.
Based upon post-treatment assessments, patients were categorized into
one of two groups: Group 1: “Improved/Resolved” (n= 34) or Group 2:
“Not-Improved/Worsened” (n = 24) compared to pre-treatment
symptoms. Informed consent/assent was reviewed and approved by the
Western Institutional Review Board (WIRB). Since this was a retro-
spective analysis, parties making assessment were not necessarily
blinded to Cunningham Panel results. All patients received medical
attention, and 56 of the 58 patients received medications including
therapy for infections and/or autoimmune disorders as potential cau-
sative factor(s) and/or psychotropic drugs for patient's neuropsychiatric
symptoms. Of the two patients who did not receive medications be-
tween testing, one patient could not afford IVIg and therefore did not
receive medication, and the other patient's medical treatment was
watchful waiting or a “tincture of time.”
2.2. Cunningham Panel assays
Whole blood or serum samples were received according to standard
operating procedures, collected in red-top glass tubes without additives
(Covidien, Monoject Red Stopper Blood Collection Tube, glass 7 mL
draw, part #8881301512). Whole blood was spun to collect serum.
Patient serum was tested according to standard operating procedures
for Moleculera Labs' CLIA/COLA accredited laboratory (CLIA Number
37D2082408). Assay protocols have been described previously (Cox
et al., 2013; Kirvan et al., 2003; Brimberg et al., 2012; Kirvan et al.,
2006a, 2006b). The threshold for a positive response for the four ELISA
assays was set at the mean value of normal controls plus two times the
standard deviation, followed by rounding to the nearest titer. In each
case, the selected threshold exceeded the 95% confidence interval for
the t-distribution. A positive titer result for DR1 is 4000 or higher, for
DR2 is 16,000 or higher, for lysoganglioside GM1 is 640 or higher, and
for tubulin is 2000 or higher. A positive result for CaMKII activation in
SK-N-SH cells was set at 130, or ≥30% above basal control sample.
Initially, a population of 20 pediatric controls utilizing designated in-
clusion/exclusion criteria was obtained from the National Institute of
Mental Health, Bethesda, MD (Courtesy of Dr. Susan Swedo) and the
Yale Child Study Center, New Haven, CT (courtesy of Dr. James
Leckman and Dr. Ivana Kawikova) (Singer et al., 2015). Since then,
additional populations of pediatric controls have been tested with si-
milar results.
2.3. Data and methods of analysis
Two distinct approaches were used to evaluate the results of these
five assays. The first method (Positive Test Count Method) counted the
change in the number of positive assays. The second method (Magnitude
of Change Method) examined the quantitative change in each of the five
assays using multivariate logistic regression analysis. The latter method
examines the magnitude of change and is independent of the cutoff
assigned by controls. Multivariate logistic regression analysis is effec-
tive when multiple test values may be better predictors compared to
any single measure, and is used in other areas of medicine for pre-
dicting treatment outcome (Sparano et al., 2018; Hambardzumyan
et al., 2015; Van Den Eeden et al., 2018).
2.3.1. Positive test count score
The Positive Test Count Score is the difference in the number of
Fig. 2. Study Flow Chart
Table 2
Age and gender distribution and mean time between the first and second Cunningham panels.
Group # Subjects Age range
(years)
Mean age
(years)
Females Males Time between first and second test
(weeks)
Mean Median
1 34 5–21 12.2 (SD = 4.02) 13 (38%) 21 (62%) 68.1 48
2 24 2–23 12.1 (SD = 5.1) 9 (38%) 15 (62%) 66.2 62
All patients 58 2–23 12.2 (SD = 4.5) 22 (38%) 36 (62%) 67.3 50
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positive tests pre-treatment, versus the number of positive tests post-
treatment. An increase in the number of positive tests results in a ne-
gative Positive Test Count Score, an unchanged number results in a
score of 0, and a decrease in the number of positive tests results in a
positive score. We represent this by the following equation: Positive Test
Count Score = (Xtub,pre + Xd1r,pre + Xd2r,pre + Xlyso,pre + XCaMKII, pre) –
(Xtub,post + Xd1r,post + Xd2r,post + Xlyso,post + XCaMKII, post) where X = 1
for a positive test and 0 for a negative test, the subscripts “tub, “d1r”,
“d2r”, “lyso” and “CaMKII” indicate the assay and the subscripts “pre”
and “post” indicate whether the assay was conducted before or after
treatment, respectively.
2.3.2. Magnitude of change score
The Magnitude of Change Score examines the magnitude of change
in post-treatment test results compared to pre-treatment. This is defined
by the equation: Magnitude of Change Score = a0 + a1*DVtub
+ a2*DVd1r + a3*DVd2r + a4*DVlyso + a5*DVCaMKII where DV = log2
(Titerpost/Titerpre) for each of the four ELISA assays and
DVCaMKII = CaMKIIvalue,post - CaMKIIvalue,pre for the CaMKII assay.
Logistic Regression Analysis, conducted in R with the glm2 (Fitting
Generalized Linear Models) package (version 1.2.1), was used to de-
termine the optimal values of the coefficients a0, a1, a2, a3, a4 and a5
and the probability of membership in either Group 1 versus Group 2 for
each patient.
The value of a0, the constant term, and coefficients a1–5 for tubulin,
D1R, D2R, lysoganglioside and CaMKII DV values in the Magnitude of
Change Score equation from our analysis are:
−0.862 ± 0.717 (p = 0.229), −1.284 ± 0.500 (p = 0.010),
−0.361 ± 0.355 (p = .310), −0.738 ± 0.438 (p = 0.093),
0.063 ± 0.288 (p = 0.826) and − 0.0461 ± 0.0172 (p = 0.007),
respectively. Null deviance and residual deviance are 78.7 and 29.7 on
57 and 52 degrees of freedom, respectively. The values of the para-
meters used in the transformation are selected to provide maximal
discrimination between Group 1 and Group 2. The probability (P) of
membership in Group 1, the group with symptomatic improvement, is
calculated from the individual's Magnitude of Change Score:
P = eMagnitude Score/(eMagnitude Score + 1). The resulting logistic regres-
sion model is then cross-validated using the “leave one out” method.
Note that Magnitude of Change Score is independent of the thresholds
used to determine individual assay results as positive or negative; in-
stead, Magnitude of Change Score is a function combining the direction
and magnitude of changes in all individual tests in the Cunningham
Panel. We investigated other models in which selected assays in the
Cunningham model were omitted; our findings were essentially un-
changed from the full model.
2.4. Reproducibility of the Cunningham Panel
Extensive reproducibility testing was conducted using patient blood
samples collected in validated glass tubes without excipients (Red Top
glass tubes), and tested repetitively at random intervals over a period of
33 months. The reproducibility testing for D1R is representative of each
of these tests. Note that a two-fold dilution scheme is used to determine
titers. To assess robustness and ongoing assay reproducibility of the
Table 3A
Patients with Improvement in Symptoms (Group 1, N = 34).
Case #
D1R D2R Tubulin
lyso-
ganglioside 
GM1
CaMKII D1R D2R Tubulin
lyso-
ganglioside 
GM1
CaMKII Pretreatment Post Treatment
6 0101108000100040002521061000100080004
72 0171108052000100573102300500020002
55 013901052000100018310800500020001
1 013802300010004000224106100500020001
30 1000 4000 500 20 143 1000 2000 1000 80 98 01
3 01380800500020001751040520001005
42 013210800010004000176104000100040002
7 0121108000100040052710800500040002
29 01311080001000400024810800010004005
26 1143104052000100011720405200010001
5 0221104052000200559046000200020002
12 0231102000100080001941023000400080002
37 0229040520001005461023000100010004
39 0211106100010004000132104600010050008
40 02221020050002052221023000400040004
74 026110610050004000133104000400080002
41 0238020520001000277102300010050008
16 12231023000100080002732023000200020002
19 128210800020004000215102000400020001
43 1284108000100040001170610008000200061
71 2213102300020004000197102000200040001
66 22831023000200080002301061000200020008
4 0380104005000800019110230004000230008
34 4000 16000 500 320 160 500 2000 500 40 118 03
54 0398010050002005651061000400040008
35 03911080001000400022910230006100020004
2 3302102300040006100083520230004000230002
45 04001080001000200023410821000400080008
9 14051080001000400023510460008000400023
13 1400108000200020001671046000400080008
17 14431020520002005931046000400020008
23 149110230001000800049310230002000610004
60 145610800500040001971080002000610008
79 1401106100010006100027610610002000610004
tsoPtnemtaerterP  treatment Number Elevated Markers
Heat Map of the Results of the Cunningham Panel. Values for patients with improvement in, or resolution of symptoms after treatment (Group 1, N= 34). The results
and the number of elevated tests before and after treatment are shown for each patient in this study. Elevated test values are highlighted in red; the intensity of color
is indicative of magnitude of elevation above threshold. The count of elevated individual tests within each patient's panels before and after treatment are indicated by
blue and orange horizontal bars, respectively.
C. Shimasaki, et al. Journal of Neuroimmunology 339 (2020) 577138
5
CaMKII assay, routine repeat testing across multiple samples was per-
formed.
3. Results
3.1. Patient demographics
Patients were either diagnosed with, or suspected of, PANS/
PANDAS at the time of their test requisition. All 58 patients presented
with various neuropsychiatric symptoms characteristic of the criteria
for PANS/PANDAS (Table 1). Age and gender distribution for all 58
patients at the time of first testing ranged from 2 to 23 years, whereas
the mean and median age for patients was 12.2 ± 4.5 and 12.0 years,
respectively. The mean time between the first and second Cunningham
Panels in Group 1 was 68.1 weeks, versus 66.2 weeks in Group 2 (p =
0.87). The median time between tests for Group 1 was 48 weeks, versus
62 weeks for Group 2. An interesting observation in examining
symptom frequency is that patients who improved with therapy (Group
1) had a higher percentage of OCD, behavioral regression and sleep
disorders, whereas those that did not improve with therapy (Group 2)
had a higher percentage of tic and movement disorders.
3.1.1. Subjects in group 1: improved/resolved in symptoms (N = 34)
The group of patients reporting symptoms Improved/Resolved post-
treatment consisted of 34 individuals ranging in age from 5 to 21 years
with a mean age of 12.2 years. There were 13 females (38%) and 21
males (62%). See Table 2.
3.1.2. Subjects in group 2: not improved/worsened in symptoms (N = 24)
The group of patients reporting symptoms Not Improved/Worsened
consisted of 24 patients ranging in age from 2 years to 23 years with a
mean age of 12.1 years. There were 9 females (38%) and 15 males
(62%), and there were no statistically significant differences in age or
gender between Group 1 and Group 2. There were no statistically sig-
nificant differences in the time between the first test and the second test
in Group 1 versus Group 2 (Table 2).
3.2. Individual results and heat map
The heat-maps (Table 3A and 3B) display the Cunningham Panel
Table 3B
Patients with no improvement in or worsening of symptoms (Group 2, N = 24).
Case #
D1R D2R Tubulin
lyso-
ganglioside
GM1
CaMKII D1R D2R Tubulin
lyso-
ganglioside
GM1
CaMKII Pretreatment Post Treatment
24 1000 8000 500 80 119 2000 8000 250 320 105 0 0
16 1000 4000 1000 20 124 2000 4000 1000 80 138 0 1
18 1000 2000 250 20 121 1000 1000 500 80 138 0 1
19 1000 250 250 160 115 2000 4000 2000 40 116 0 1
34 2000 2000 500 320 121 2000 8000 1000 20 145 0 1
77 500 2000 1000 20 126 1000 2000 2000 40 141 0 2
29 1000 2000 500 80 138 1000 2000 250 160 1721 0
62 2000 4000 1000 80 216 2000 2000 500 80 1321 0
64 500 2000 250 320 134 1000 4000 2000 80 11521
104 2000 4000 1000 40 149 2000 4000 1000 40 11571
45 2000 4000 500 80 217 4000 4000 2000 80 31851
8 1000 8000 1000 40 219 4000 16000 1000 320 31931
38 1000 1000 1000 160 179 8000 8000 4000 1280 1041 4
48 1000 2000 2000 80 156 2000 8000 1000 160 12541
36 2000 16000 1000 160 164 8000 8000 4000 160 22321
122 500 8000 1000 640 136 2000 4000 4000 320 22341
20 2000 2000 2000 40 164 4000 16000 8000 160 2051 4
42 32000 4000 2000 80 112 4000 16000 2000 160 2461 4
55 2000 8000 2000 320 160 4000 16000 8000 80 2251 4
39 8000 250 2000 160 159 2000 16000 4000 80 33261
26 4000 32000 8000 320 94 8000 16000 8000 1280 53771
14 8000 4000 2000 640 148 8000 16000 16000 40 92 4 3
63 8000 32000 2000 320 142 32000 32000 8000 640 113 4 4
35 54941082100040002300080310610004000230004
tsoPtnemtaerterP treatment Number ElevatedMarkers
Heat map of the results of the Cunningham Panel. Values for patients with no improvement in, or worsening of symptoms after treatment (Group 2, N = 24). The
results and the number of elevated tests before and after treatment are shown for each patient in this study. Elevated test values are highlighted in red; the intensity of
color is indicative of magnitude of elevation above threshold. The count of elevated individual tests within each patient's panels before and after treatment are
indicated by blue and orange horizontal bars, respectively.
Table 4
Patient numbers by group: impact of treatment on Cunningham Panel tests, Comparison of the number of patients showing improvement in symptoms with those
showing a decrease in the number of individual positive assays in the Cunningham Panel by populations described in Table 3A and 3B. The p-value was calculated
using the Fisher exact test.
Resolved
(No positive test post-
treatment)
Decreased Count
(not resolved)
Unchanged
(at least 1 positive 
test)
Increased
1 34 21 (62%) 9 (26%) 4 (12%) 0 (0%) 0 (0%) 30 (88%) 4 (12%)
2 24 2 (8%) 2 (8%) 6 (25%) 13 (54%) 1 (4%) 4 (17%) 19 (79%)
Group N
No Posi ve Tests
(Pre- or 
Posttreatment)
p value
1.33E-07
Total Resolved or
Decreased
Number Posi ve Tests Post-Treatment vs. Pretreatment
Total Increased or
Unchanged
Total Resolved or
Decreased (%)
Total Increased or
Unchanged (%)
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results pre- and post-treatment for all patients. Individual titers high-
lighted in red indicate a positive abnormal assay with the intensity of
color indicating the extent of elevation. Titers without color highlighted
indicate a normal assay value. The change in the Cunningham Panel
results is highly associated with the reported change in symptoms fol-
lowing treatment as summarized in Table 4. The number of patients
with elevated individual test results pre-treatment and post-treatment
are shown in Fig. 3. The mean values for each of the individual tests in
the Cunningham Panel before and after treatment are shown in Sup-
plemental Fig. 1.
We evaluated the data for any association between changes in
Cunningham Panel results and changes in patient symptoms after
treatment or medical intervention using two distinct approaches: the
Positive Test Count Method and the Magnitude of Change Method.
Results from both analyses are summarized in the 2 × 2 contingency
tables for sensitivity, specificity and accuracy (Fig. 4A and 5A), whereas
the respective Receiver Operating Characteristic (ROC) curves are
shown in Fig. 5A and 5B. The dot plots of individual scores by group
and by analysis are shown in Fig. 4C and 5C.
Fig. 3. Number of patients with elevated test result.
Fig. 4. Results for the Cunningham Panel Test (Positive Test Count Score Method).
4A. Sensitivity and specificity of Cunningham Panel assays: 2 × 2 matrix and calculation of sensitivity, specificity and accuracy using Change in Number of Positive
Tests ≥0.5 as predicting membership in Group 1 (optimum from ROC curve).
4B. Receiver Operating Characteristic (ROC) curve of Cunningham Panel assay results.
4C. Dot Plots for Change in Number Positive Tests. Blue dotted line (y = 0.5) shows threshold used in assigning membership in 2 × 2 matrix. (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article.)
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3.2.1. Positive test count method
This method consists of assessing change in Cunningham Panel re-
sults (positive or negative) upon treatment by tallying the number of
positive tests for each of the five assays. A 2 × 2 contingency table
analysis (p = 5 × 10−8, Fisher exact test) revealed an 88% sensitivity,
83% specificity, and an accuracy of 86% (Fig. 4A). The ROC curve had
an AUC of 93.4% (Fig. 4B). Dot plots of individual scores revealed good
separation by group (Fig. 4C).
In the patients reporting symptom improvement following treat-
ment, 88% (30/34) demonstrated a decrease in the number of in-
dividual positive Cunningham Panel tests. Within these patients, 62%
(21/34) had all tests become negative whereas 26% (9/34) showed
reduction in the number of positive tests and 12% (4/34) demonstrated
an unchanged number of positive tests. No patients in the Improved/
Resolved group had an increase in the number of positive tests post-
treatment (Table 4). For patients whose symptoms failed to improve or
worsened post-treatment (Group 2), 79% (19/24) demonstrated either
the same number of positive tests pre-treatment or an increase in the
number of positive tests in their panel. Within these patients, 54% (13/
24) revealed an increase in the number of individual positive tests, with
25% (6/24) having an unchanged number of individual positive tests,
and 8% (2/24) with a decrease in the number of positive tests in their
panel.
3.2.2. Magnitude of change method
Using linear logistic regression we created an optimal function de-
rived from the magnitude of change in the Cunningham Panel test
scores which separated the groups of patients who responded to treat-
ment vs those that did not respond. This multivariate method analysis
creates a linear transformation which reduces the five individual values
comprising the Cunningham Panel into one composite or combined
score. Null deviance and residual deviance are 78.7 and 29.7 on 57 and
52 degrees of freedom, respectively. Accordingly, R2 = 0.62. In con-
trast to linear regression, R2 is not related to any correlation coefficient,
nor is it a percentage of variance explained by the logistic model, rather
it is a ratio indicating how close the fit is to being perfect (R2 = 1) or
Fig. 5. Results for the Cunningham Panel Test (Magnitude of Change Score Method).
5A. Sensitivity and specificity of Cunningham Panel assays: 2 × 2 matrix and calculation of sensitivity, specificity and accuracy using Probability Threshold ≥0.539
as predicting membership in Group 1 (optimum from ROC curve).
5B. Receiver Operating Characteristic (ROC) curve of Cunningham Panel assay results.
5C. Dot Plots for Magnitude of Change scores. Blue dotted line (y = 0.539) shows threshold used in assigning membership in 2 × 2 matrix. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Individual CaMKII assay results from the Cunningham panel before and
after treatment and grouped by effect of treatment on patient symptoms. P
values are from a paired sample t-test.
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the worst possible (R2 = 0). As part of characterization of model
quality, a summary of the values for all coefficients in “leave-one-out”
analysis are shown in Supplemental Table 1. The probabilities for the
misclassification in the original and leave-one-out validation are given
in Supplemental Table 2.
Results in the 2 × 2 contingency table (p= 6× 10−10, Fisher exact
test) revealed an 88% sensitivity, 91% specificity with an overall ac-
curacy of 90% (Fig. 5A). Values in 5A are taken from a threshold:
0.522 < Probability< 0.557 which provides highest values per the
ROC analysis in 5B. For example, if the threshold is set at 0.5, then the
number of incorrect assignments of Group 2 to Group 1 increases from 2
to 3 of 24 whereas the number of incorrect assignments of Group 1 to
Group 2 is unchanged at 4 of 34 (Supplemental Table 2) for an overall
accuracy of 88%. The ROC curve used to define the threshold for pre-
dicting inclusion in Group 1 or Group 2 resulted in an AUC of 95.7%
(Fig. 5B). Dot plots of individual scores revealed good separation by
group (Fig. 5C). We find that there is good discrimination between
Group 1 and Group 2 based on quantitative changes in the test results.
There is an interesting trend observed for patients in Group 1;
CaMKII values were, more often than not, elevated prior to treatment
and then significantly decreased in conjunction with a reduction in
symptoms post-treatment (p =0.000004), approaching levels asso-
ciated with normal control populations (Fig. 6). In contrast, those pa-
tients in Group 2, defined as those whose symptoms did not improve
post-treatment, tended to show elevated CaMKII levels both before and
after treatment without any statistically significant change post-treat-
ment (p =0.311) (Fig. 7).
3.3. Summary of treatments and comparisons between groups
Retrospective evaluation of treatments revealed that of patients
treated with immunotherapy (IVIg, plasmapheresis, Rituximab, or
combination) 66.7% improved (Group 1), while just 33.3% failed to see
improvement (Group 2). For patients who were treated with anti-
microbial therapy alone, 70.6% of patients experienced symptom im-
provement vs. 29.4% failing to improve or worsening. Overall, treat-
ment with multiple classes of therapeutic interventions in most cases
showed modestly higher percentages of improvement, whereas in pa-
tients treated with psychotropic medications, dietary changes, or un-
treated, only 20% of patients reported symptom improvement. More
specifically, four of four patients (100%) improved with combined IVIg
and plasmapheresis, and one of two patients (50%) improved with
combined IVIg and Rituximab. Only one of five (20%) patients im-
proved who were treated with psychotropic medications, dietary
changes, or no treatment (see Table 5). Note that in general, the utili-
zation frequency of specific treatments is similar between Group 1 and
Group 2 (Table 5). The use of “Immunotherapies Only” and “Anti-
microbials Only” is somewhat higher in Group 1 than in Group 2,
whereas the percentage of patients in Group 2 that received both classes
of therapy is somewhat higher than in Group 1.
Fig. 7. CaMKII assay result trend lines of individual patent results in Group 1
and Group 2. Pre- and post-treatment values are connected by solid lines. P
values are from a paired sample t-test.
Table 5
Summary of treatments and outcomes. Binary classification of response to treatment (Improvement vs No Improvement / Worsened by therapeutic modality [i.e.
antimicrobial therapy, immunotherapy, combination of these therapies, other]). * % Improved indicates the percent of patients whose symptoms improved with the
corresponding therapy(ies). ** % of group receiving this therapy.
Treatment Description Group 1
Improved
Group 2
No improvement or worsened
% improved *
A All therapies containing antimicrobials 19 (56%)** 13 (54%) 59.4%
B All therapies containing immunotherapies 21 (62%) 15 (63%) 58.3%
C Antimicrobials only 12 (35%) 5 (21%) 70.6%
D Immunotherapies only 14 (41%) 7 (29%) 66.7%
Individual Immunotherapies
IVIg 9 5 64.3%
Plasmapheresis 1 1 50.0%
Rituximab 1 0 100.0%
Combination Immunotherapies
IVIg Plasmapheresis 4 0 100.0%
IVIg Rituximab 1 1 50.0%
E Antimicrobials + Immunotherapies 9 (26%) 8 (33%) 52.9%
IVIg 6 7 46.2%
Plasmapheresis 0 1 0.0%
IVIg Plasmapheresis 3 0 100.0%
IVIg Plasmapheresis Rituximab 0 1 0.0%
F Antimicrobial, immuno- or combination thereof 33 (97%) 20 (83%) 62.3%
G Other/none 1 (3%) 4 (17%) 20.0%
Psychotropic medications only 0 1 0.0%
Dietary changes only 1 1 50.0%
No treatment 0 2 0.0%
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3.4. Reproducibility of ELISA testing in the Cunningham Panel
For repeated D1R assay we observed 207 readings at the same titer,
62 readings at one titer higher and 75 readings at one titer lower
(Fig. 8), resulting in a distribution of 17.3%, 61.5% and 21.2%, re-
spectively. No results were greater than one titer dilution away from the
peak. When expanded to include mixed patient samples and ad-
ditionally processed or concentrated patient samples, we saw rare in-
stances (< 0.5%) where the assigned titer was two dilution steps from
the peak. In no cases were any titers greater than two dilution steps
from the peak.
3.5. Reproducibility of CAMKII assay results in the Cunningham panel
Seventeen samples underwent repeat CaMKII assay testing. The
correlation between the original and the repeat test was 0.90
(p < 1.67 × 10−6) and the root-mean-square deviation (RMSD) is
13.8 (Fig. 8B). The deviation (Repeat Assay Value / Original Assay
Value) was approximately 15% with no apparent dependence on the
actual CaMKII activity over the range of values routinely measured. The
baseline value by definition is 100, whereas the threshold for a positive
in the CaMKII assay is set at 130 (30% above baseline values defined
from measurements in pediatric controls).
In summary, repetitive testing of multiple samples, multiple times in
the ELISA and CaMKII assays using patient samples demonstrates assay
robustness and reproducibility.
4. Discussion
For PANDAS and PANS, there is a need to elucidate the pathophy-
siology and underlying disease mechanisms in order to improve the
identification of patients, advance targeted therapies, and to clarify the
characteristics of these disorders. The value of identifying a group of
biomarkers that correspond to a disease etiology is that it can segment
patients exhibiting similar symptoms into groups that can be adminis-
tered different treatment modalities based upon their underlying dis-
ease etiology. In this 58 patient case series, we found that changes in
assays of the Cunningham Panel parallel changes in patient symptoms
following treatment. Using the change in the number of positive tests
we were able to predict change in symptoms with an accuracy of 86%
and sensitivity and specificity of 88% and 83%, respectively. Based
upon the magnitude of change of individual test values of the
Cunningham Panel, we were able to predict change in symptoms with
an accuracy of 90%, a sensitivity of 88% and a specificity of 92%.
4.1. Comparison with other published studies
In a 2018 study of 80 patients having a diagnosis of ASD, in which
31 children with autoimmune encephalopathy received IVIg treatment,
the Cunningham Panel predicted patient improvement and response to
IVIg treatment with an accuracy of 81%, a sensitivity of 90% and a
specificity of 67% based on the Aberrant Behavior Checklist (ABC)
scores; with an accuracy of 88%, a sensitivity of 100% and a specificity
of 75% based on the Social Responsiveness Scale (SRS) scores; and with
an accuracy of 88% with a sensitivity of 100% and a specificity of 67%
based on parental scores (Connery et al., 2018). The sensitivity and
specificity of the Cunningham Panel in predicting IVIg responsiveness
in children with autoimmune encephalopathy and diagnosed with ASD
(81% to 88%) are similar to the performance accuracy we observed in
this study (87% to 90%). Published literature reveals that children with
ASD have strong family histories of immune dysregulation and in-
flammation, and that the literature supports a strong association of
immune dysregulation and ASD (Rossignol and Frye, 2012). Because
Fig. 8. Fig. 8A. D1R ELISA assay reproducibility. These are the summary of results for various control samples tested repeatedly between 3/29/2014 and 12/29/
2016.
Fig. 8B. CaMKII assay reproducibility. Each data point represents a single specimen; the x value is the CaMKII score from the first measurement and y value is the
CaMKII score from a second measurement. The solid line is the best-fit line to the experimental data.
Autoimmune 
Encephalopathy of 
Infectious Etiology
PANDAS and PANS ADD
ADHD
Seizure 
Disorders
Autism 
Spectrum 
Disorder
OCD
Tics
Fig. 9. Illustration of underlying etiology as the basis for symptoms or clinical
diagnoses.
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current diagnostic criteria for ASD and PANDAS/PANS are based upon
clinical symptom clusters (Chang et al., 2015), it is possible that a
common underlying etiology of these disorders, or a subset of these
clinical syndromes, may be immune dysregulation with antineuronal
antibodies directed against the basal ganglia and/or other CNS targets
in the brain.
A 2017 study questioned the clinical utility of the Cunningham
Panel (Hesselmark and Bejerot, 2017a) based upon a retesting study of
53 patients, with 46 patients having a repeat test. The estimated sen-
sitivity for individual tests ranged from 15% to 60% and the estimated
specificity ranged from 28% to 92%. Shortly thereafter, the authors
submitted a Corrigendum (Hesselmark and Bejerot, 2017b) acknowl-
edging they had unknowingly utilized invalid blood collection tubes
containing clot activators and serum separator gels (BD Vacutainer®
SST™ II Advance tubes, Gold Top) which are not acceptable for col-
lecting Cunningham Panel samples. Specimens collected in blood tubes
containing excipients or additives have the potential for irreproduci-
bility of results, potential interactions with patient's specimens, and
potential direct interference in the assays.
In the referenced study, the authors reported some “healthy con-
trols” showing positive Cunningham Panel results. This could be a re-
sult of the invalid collection method or the exclusion and inclusion
criteria utilized for their control population (Frye and Shimasaki,
2019). Family history of psychiatric, autoimmune, or movement dis-
order was not investigated in the controls nor was the history of recent,
chronic or recurrent infections. Since PANDAS/PANS is often triggered
by an infection which can be subclinical or occult, transient molecular
mimicry could have confounded test results. More importantly, al-
though the patients were asked about a psychiatric or autoimmune
diagnosis, symptoms of autoimmune or psychiatric disorders were not
specifically investigated. This lack of detailed screening of the controls
calls into question the extent to which the controls were verified as
healthy.
4.2. Therapeutic interventions
Although this current study was not designed as a comparison of
treatment interventions, within those whose symptoms improved post-
treatment, a greater percentage received some form of im-
munomodulatory or antimicrobial therapy alone, compared to the pa-
tient group whose symptoms did not improve. It was observed that a
higher percentage (70.6%) of patients improved who were treated with
antimicrobial therapy alone, whereas 52.9% of patients treated with
both modalities saw improvement. It is unknown whether those pa-
tients who required multiple therapeutic modalities may have had
longer duration of illness or greater severity of symptoms. PANDAS/
PANS patients typically have undergone multiple symptomatic-focused
treatments prior to a recognition of their underlying infectious trigger
and autoimmune etiology. It may be that prolonged duration of these
conditions prior to proper diagnosis and treatment could impact the
outcome of a course of therapy and the treatment duration required to
observe symptom resolution in these patients.
A confounding issue that could potentially influence the outcome of
certain immunomodulatory treatments with IVIg is the observation that
in some IVIg lots we tested, we find varying, but significantly elevated
levels of antineuronal antibodies against the biological targets and
CaMKII activation in the Cunningham Panel (data not shown). Because
IVIg is a product produced through the concentration of im-
munoglobulins from 1000 or more patients, it would not be unexpected
to observe this. However, it is key that post-treatment testing with the
Cunningham Panel be performed after significant clearance of potential
exogenous antineuronal antibodies, as this may confound patient re-
sults. Estimates of half-life of some manufacturers' IVIg are as long as
40 days in patients (IVIg Manufacturer's Package Insert). Also, in a
research setting where testing was performed at regular intervals
during immunomodulatory treatment, completely normal testing
results have been observed, due to the possibility of im-
munomodulatory treatment interfering with testing results, either by
suppressing the production of these autoantibodies or direct inter-
ference. Because of potential for immunomodulatory treatment inter-
ference with test results, prescribers are advised to consider waiting at
least six to eight weeks or longer following treatment to determine
treatment effectiveness in reducing these antineuronal antibodies.
Within this study the mean time from pre-treatment testing to post-
treatment testing was 68.1 and 66.2 weeks respectively for Group 1 and
Group 2.
4.3. Future directions
There is a clear need for more treatment practice guidance for post-
infectious autoimmune neuropsychiatric disorders. The recently pub-
lished treatment guidelines for patients with PANS/PANDAS (Swedo
et al., 2017; Thienemann et al., 2017; Frankovich et al., 2017;
Cooperstock et al., 2017) and clinical and treatment information on the
PANDAS Physician Network (PPN) (‘PANDAS Physican Network'',
2018) will help establish a standard for treatment of these patients.
Additionally, in order to help guide treatment decisions, we are sys-
tematically analyzing our biobank of over 8000 annotated samples to
study how baseline data may help stratify patient populations into di-
agnostic subgroups for predicting treatment response.
Other clinical reports have been published showing effective utili-
zation of immunomodulatory treatment for autoimmune encephalitis
based upon the presence of antineuronal antibodies directed against
NMDA receptor (Dalmau et al., 2017), voltage-gated potassium
channel-complex (VGKC) (Vincent et al., 2011), leucine-rich glioma
inactivated-1 (LGI1), astrocyte aquaporin-4 (AQP4) (Zekeridou and
Lennon, 2015), glutamic acid decarboxylase (GAD65), gamma-amino-
butyric acid-B receptor (GABAB), and others (Mader et al., 2017; Platt
et al., 2017; Mohammad and Dale, 2018; Lancaster, 2016; Dale et al.,
2017). It is plausible there could be additional antineuronal antibody
targets that lead to symptoms of autoimmune encephalitis. Interest-
ingly, in a study of 61 patients diagnosed with autoimmune encephalitis
by confirmatory testing such as MRI, CSF inflammation, EEG and FDG-
PET/CT, it was determined that the anti-neuronal antibodies in this
referenced study, such as those listed above, did not account for 48%
(29/61) of these patients presenting with autoimmune encephalitis
(Probasco et al., 2017). A future study will include the examination of a
broader range of anti-neuronal antibodies. Thus, while there are many
known targets for autoantibodies in patients with autoimmune en-
cephalopathies, antibodies to extracellular epitopes of dopamine D2
receptor have also been identified in patients with pediatric basal
ganglia encephalitis (Dale et al., 2012) a related disorder with over-
lapping yet distinct clinical presentation to PANDAS/PANS.
5. Study limitations
Pre- and post-treatment symptom responses were carefully collected
and documented by questionnaire and telephone follow-up with par-
ents and physicians. However, because of the lack of a standardized
instrument and a single individual assessing symptom severity in all
these patients, there could be inter-patient variation in the self-re-
porting of symptom severity. Future studies would benefit from the
utilization of a standardized rating scale in a single study utilizing a
single independent assessor for measuring the severity of symptoms.
Since PANS/PANDAS is a diagnosis of exclusion and patients currently
may not receive this diagnosis during a primary medical visit, patients
that are referred for testing may have visited multiple clinicians and
received multiple therapies that have failed prior to their Cunningham
Panel. Thus, there might be significant variability between symptom
onset and initial testing with the Cunningham panel.
Other limitations to this study include the relatively small sample
sizes of patients in each group, which was limited to the numbers of
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patients that had pre- and post-treatment testing during this interval,
and the relatively small number of carefully screened pediatric healthy
controls from which the normal or basal levels were obtained.
Although published literature has demonstrated that anti-infectives
and immune modulatory therapy can indeed be effective in PANDAS
patients (Kovacevic et al., 2015; Perlmutter et al., 1999), the exact
treatment used, dose and duration of treatment and when the treatment
was instituted was not controlled as part of this study and could have
added to variability.
Interestingly, autoantibodies against certain biomarkers have also
been identified in other inflammatory, movement, and/or neu-
ropsychiatric conditions. Although autoantibodies against any in-
dividual target may not be diagnostic for PANDAS/PANS or Sydenham's
chorea, the entire panel taken together may be a strong aid in a phy-
sician's clinical diagnosis of an autoimmune etiology. There also re-
mains the possibility that autoantibodies against these targets may not
necessarily be pathogenic but rather an epiphenomena associated with
this disorder. Further research and clinical studies are in progress to
assess this as a causal contribution or a downstream result of the dis-
order.
6. Conclusions
We report here for the first time a strong positive association be-
tween the change in anti-neuronal antibody titers and antibody-medi-
ated CaMKII activation measured as part of the Cunningham Panel and
change in neuropsychiatric symptoms in patients with PANDAS/PANS.
These data provide supportive evidence that the change in levels of
serum autoantibodies directed against neuronal pathophysiological
processes may correlate with the change in neuropsychiatric symptoms
in patients with certain neuropsychiatric disorders.
These observations and results support a potential common pro-
posed mechanism where infection-triggered immune dysregulation may
lead to antineuronal antibodies directed against specific targets in the
brain resulting in neuropsychiatric symptoms (Labrie and Brundin,
2019). A Danish study by Köhler-Forsberg et al. of over one million
individuals provides compelling epidemiologic evidence that severe
infections are linked to the onset of neuropsychiatric illnesses in chil-
dren (Kohler-Forsberg et al., 2019). They observed an 8-fold increased
risk for obsessive-compulsive disorder in teenagers, and the study
identified a 1.5-fold to 5.6-fold elevated risk for neurodevelopmental
delay, mental retardation, and behavioral and/or emotional dis-
turbances in the young. If this mechanism proves to be true, there is the
potential that subsets of other clinically-defined neuropsychiatric dis-
orders and conditions may have a pathophysiology representing a
broader category of disorders referred to as “Autoimmune En-
cephalopathies of Infectious Etiology,” (Fig. 9 Graphical Abstract).
In an era of precision medicine, there would be clinical advantages
if targeted testing could segment patients having heterogeneous
symptoms into discrete groups based upon responsiveness to a parti-
cular treatment modality. Although the historical identification of the
anti-neuronal antibodies in the Cunningham Panel originated from
patients diagnosed with Sydenham chorea and later PANS/PANDAS
patients, these biomarker targets may help identify broader populations
of patients experiencing neuropsychiatric symptoms triggered by a si-
milar autoimmune etiology that may be responsive to immune mod-
ulation therapy. Testing results may also provide a clinician with the
biological evidence for the diagnosis of an immune-mediated disorder
which may alter their treatment modality.
Based upon this retrospective analysis, there is evidence to support
that the Cunningham Panel may have value as an aid in a clinician's
diagnosis and management of patients with PANDAS/PANS. Although
it is not clear whether the presence of antineuronal antibodies to these
targets may be causal or an associative response to a patient's neu-
ropsychiatric symptoms, identifying such an objective measure is es-
sential for performing future studies on treatment outcomes and to help
elucidate a disease mechanism. The results of this study represent a step
towards validating antineuronal antibody tools that may be utilized as
an aid in a physician's diagnosis of PANDAS/PANS and support future
prospective studies into the understanding of its etiology and patho-
genesis. The validation of biological markers may also lead to the
identification and development of more efficacious targeted ther-
apeutics for treating patients with these neuropsychiatric disorders.
Further, the data generated in this study suggests a larger analysis is
warranted including more patients to explore whether baseline data can
predict treatment response in patients with neuropsychiatric symptoms.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jneuroim.2019.577138.
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